Table 1.
Marker name | Effects | References |
---|---|---|
Extracellular markers | ||
CD117/c-kit | Tumor progression | [37] |
Metastatic colonization and growth | [60, 61] | |
Recurrence and therapeutic resistance | [37] | |
| ||
CD133 | Tumor progression | [25, 95, 96] |
Self-renewal capacity | [31, 95, 97, 98] | |
Stemness gene expression | [23, 99] | |
| ||
CD44 | Tumor progression | [96, 100] |
Self-renewal capacity | [30, 31, 40, 41, 97, 101] | |
Stemness gene expression | [41, 99] | |
Metastatic colonization and growth | [102] | |
| ||
α 2 β 1 integrin | Tumor progression | [25, 50, 63] |
Self-renewal capacity | [30, 31] | |
Recurrence and therapeutic resistance | [63] | |
| ||
α 6 integrin | Tumor progression | [63] |
Self-renewal capacity | [101, 103] | |
Recurrence and therapeutic resistance | [63] | |
| ||
CXCR4 | Tumor progression | [88, 104] |
Self-renewal capacity | [70] | |
Metastatic colonization and growth | [58, 62] | |
Recurrence and therapeutic resistance | [62, 70] | |
| ||
E-cadherin | Stemness gene expression | [20, 36] |
Metastatic colonization and growth | [65] | |
Therapeutic resistance | [29] | |
| ||
EpCAM | Tumor progression | [33, 59, 71] |
Metastatic colonization and growth | [59, 90] | |
Recurrence and therapeutic resistance | [33, 71, 72] | |
| ||
Cytokeratin 5 | Tumor progression | [67] |
Self-renewal capacity | [103] | |
| ||
PSAlo | Tumor progression | [38] |
Self-renewal capacity | [38] | |
Stemness gene expression | [38] | |
Recurrence and therapeutic resistance | [100] | |
| ||
ABCG2 | Recurrence and therapeutic resistance | [49, 73, 75] |
| ||
Trop2 | Tumor progression | [25, 105] |
Self-renewal capacity | [91, 92, 101, 103] | |
| ||
AR variant 7 | Recurrence and therapeutic resistance | [79, 81, 82] |
| ||
CD166/ALCAM | Tumor progression | [39, 106] |
Self-renewal capacity | [39] | |
Recurrence and therapeutic resistance | [39] | |
| ||
Intracellular markers | ||
ALDH1 | Tumor progression | [47, 48, 51, 100, 107] |
Self-renewal capacity | [30, 47, 107] | |
Stemness gene expression | [49] | |
Recurrence and therapeutic resistance | [47, 49, 100] | |
| ||
TG2 | Tumor progression | [77] |
Recurrence and therapeutic resistance | [77, 78] | |
| ||
EZH2 | Tumor progression | [50, 96] |
Stemness gene expression | [108] | |
Metastatic colonization and growth | [51, 68] | |
Recurrence and therapeutic resistance | [29, 50, 69] |
EZH2: enhancer of zeste homolog 2; ALDH1: aldehyde dehydrogenase 1; ABCG2: ATP-binding cassette G2; PSA: prostate-specific antigen; TG2: transglutaminase 2. Self-renewal capacity includes sphere formation, colony formation, clonogenic assays, and limiting dilution assays. Stemness gene expression includes Sox2, Oct3/4, Nanog, c-myc, and/or Klf4.